TY - JOUR T1 - Prevalence of previous infection with SARS-CoV-2 and persistent symptoms at a large university JF - medRxiv DO - 10.1101/2021.07.08.21260201 SP - 2021.07.08.21260201 AU - Mark H. Ebell AU - David Forgacs AU - Ye Shen AU - Ted M. Ross AU - Cassie Hulme AU - Michelle Bentivegna AU - Hannah B. Hanley AU - Alexandria M. Jefferson AU - Lauren Haines Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/10/2021.07.08.21260201.abstract N2 - Importance Universities are unique settings with large populations, congregate housing, and frequent attendance of events in large groups. However, the prevalence of previous infection with SARS-CoV-2 in university students, including symptomatic and asymptomatic disease, is unknown.Objective To determine the prevalence of previous infection, risk factors for infection, and the prevalence of persistent symptoms following infection among university students.Design This was a cross-sectional study that surveyed students about demographics, risk factors, and symptoms, and simultaneously tested their saliva for IgA antibodies to SARS-CoV-2. To estimate the prevalence of previous infection we adjusted our intentional sample of a diverse student population for year in school and age to resemble the composition of the entire student body, and adjusted for the imperfect sensitivity and specificity of the antibody test. Univariate and multivariate analysis was used to identify independent risk factors for infection.Setting A large public university in Athens, Georgia between January 22 and March 22, 2021.Participants Undergraduate and graduate students; 488 completed the survey, 432 had a valid antibody result. and 428 had both.Exposure Previous infection with SARS-CoV-2 based on measurement of IgA antibodies in saliva and adjustment for sample characteristics and test accuracy.Main Outcomes and Measures The primary outcome was the estimated prevalence of previous infection with SARS-CoV-2. Secondary outcomes were independent risk factors for infection, and the prevalence of persistent symptoms among persons reporting a previous symptomatic infection.Results The estimated prevalence of previous infection for 432 participants with valid antibody results was between 41% and 42%. Independent risk factors for infection included male sex, having a roommate with a known symptomatic infection, and having 2 or fewer roommates. More frequent attendance of parties and bars was a univariate risk factor, but not in the multivariate analysis. Of 122 students reporting a previous symptomatic infection, 14 (11.4%) reported persistent symptoms a median of 132 days later.Conclusions and Relevance Previous infection with SARS-CoV-2, both symptomatic and asymptomatic, was common at a large university. Measures that could prevent resurgence of the infection when students return to campus include mandatory vaccination policies, mass surveillance testing, and testing of sewage for antigen to SARS-CoV-2.Question What is the prevalence of previous infection with SARS-CoV-2 and the prevalence of persistent symptoms in university students?Findings In this sample of 432 students who provided saliva for IgA antibodies, we estimate that 41% to 42% had evidence of previous infection. Of 122 reporting a previous symptomatic infection, 14 (11%) were still symptomatic a median of 132 days later.Meaning Symptomatic and asymptomatic infections with SARS-CoV-2 are common among university students, and a significant percentage had persistent symptoms over a long duration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was self-funded by the investigators.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Human Subjects Committee at the University of Georgia (Version 00000889, Project 00003338). All participants gave written informed consent prior to participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available as further analysis is ongoing by the co-authors as part of a thesis. They will be made available upon reasonable request when this analysis is completed. ER -